842133-18-0 low price global Canagliflozin

Superiority:

842133-18-0 low price global Canagliflozin

Canagliflozin (canagliflozin) is an SGLT2 inhibitor drug that lowers blood sugar by breaking down glucose and excreting it through the kidneys. In addition to good blood sugar control, canagliflozin (canagliflozin) ) Canagliflozin's most eye-catching effect is weight loss and few hypoglycemic events, which has broad prospects. 
On June 9, 2012, according to the results of two phase III clinical trials, Johnson & Johnson's (JNJ) experimental type 2 diabetes drug canagliflozin was superior to Merck’s Januvia and another old drug glimepiride in terms of lowering blood sugar. At the same time, canagliflozin has a more significant weight loss effect; compared with glimepiride, canagliflozin causes far fewer hypoglycemic events. On January 11, 2013, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, announced on the 10th that its diabetes drug canagliflozin (trade name INVOKANA?) was approved by the FDA expert committee 10:5 vote for the treatment of adult type 2 diabetes. 
On March 29, 2013, the U.S. Food and Drug Administration (FDA) approved Canagliflozin (trade name Invokana, Johnson & Johnson's Janssen Pharmaceutical Company) to improve blood glucose control in adults with type 2 diabetes. On November 25, 2013, Janssen, a subsidiary of Johnson & Johnson (JNJ), announced that INVOKANA (canagliflozin), a new diabetes drug, has been approved by the European Commission (EC) for the treatment of adults with type 2 diabetes to improve blood sugar control. In September 2014, canagliflozin (Canagliflozin) received a positive recommendation approved by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). In addition, canagliflozin (Canagliflozin) has been approved by the FDA in March this year, and has recently received approval from Australia.